Evaluate the Safety and Clinical Activity of HH2853
Conditions
FL Lymphoma · Epithelioid Sarcoma · Peripheral T Cell Lymphoma · Advanced Solid Tumor
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic, Phoenix, Arizona, United States
Mayo Clinic, Jacksonville, Florida, United States
Mayo Clinic, Rochester, Minnesota, United States
NEXT Oncology, San Antonio, Texas, United States
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Beijing Jishuitan Hospital, Beijing, Beijing Municipality, China
Sun Yat-Sen University Cancer Hospital, Guangzhou, Guangdong, China
Contact: Principal Investigator (Jundong Li)Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China
Contact: Principal Investigator (Weimin Xie)Henan Cancer Hospital, Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Contact: Principal Investigator (Jing Chen)Hunan Cancer Hospital, Changsha, Hunan, China
Contact: Principal Investigator (Xianan Li)Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China
Liaoning Cancer Hospital&Institute, Shenyang, Liaoning, China
Shengjing Hospital Of China Medical University, Shenyang, Liaoning, China
Linyi Tumor Hospital, Linyi, Shandong, China
Shanghai Sixth People's Hospital, Shanghai, Shanghai Municipality, China
Zhongshan Hospital Fudan University, Shanghai, Shanghai Municipality, China
Shanxi Cancer Hospital, Taiyuan, Shanxi, China
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Contact: Study coordinator (Yu Jiang)Tianjin Cancer Hospital, Tianjin, Tianjin Municipality, China
Contact: Principal Investigator (Jilong Yang)Contact: Principal Investigator (Yun Yang)Contact: Principal Investigator (Shiyong Zhou)Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Contact: Principal Investigator (Haiyan Yang)Beijing Cancer Hospital, Beijing, China
Sun Yat-Sen University Cancer Hospital, Guangzhou, China
Study leads
Fugen Li
Study Director
Haihe Biopharma Co., Ltd.